Pharma Reaserch Prod Co Ltd - Asset Resilience Ratio
Pharma Reaserch Prod Co Ltd (214450) has an Asset Resilience Ratio of 42.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Pharma Reaserch Prod Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Pharma Reaserch Prod Co Ltd's Asset Resilience Ratio has changed over time. See Pharma Reaserch Prod Co Ltd (214450) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Pharma Reaserch Prod Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pharma Reaserch Prod Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩438.71 Billion | 42.03% |
| Total Liquid Assets | ₩438.71 Billion | 42.03% |
Asset Resilience Insights
- Very High Liquidity: Pharma Reaserch Prod Co Ltd maintains exceptional liquid asset reserves at 42.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pharma Reaserch Prod Co Ltd Industry Peers by Asset Resilience Ratio
Compare Pharma Reaserch Prod Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Pharma Reaserch Prod Co Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Pharma Reaserch Prod Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.03% | ₩438.71 Billion ≈ $297.31 Million |
₩1.04 Trillion ≈ $707.43 Million |
+10.24pp |
| 2024-12-31 | 31.79% | ₩272.00 Billion ≈ $184.33 Million |
₩855.70 Billion ≈ $579.90 Million |
+14.40pp |
| 2023-12-31 | 17.38% | ₩93.05 Billion ≈ $63.06 Million |
₩535.28 Billion ≈ $362.75 Million |
-21.18pp |
| 2022-12-31 | 38.56% | ₩184.34 Billion ≈ $124.92 Million |
₩478.06 Billion ≈ $323.97 Million |
+1.89pp |
| 2021-12-31 | 36.66% | ₩156.79 Billion ≈ $106.26 Million |
₩427.65 Billion ≈ $289.81 Million |
+11.88pp |
| 2020-12-31 | 24.78% | ₩79.26 Billion ≈ $53.72 Million |
₩319.83 Billion ≈ $216.75 Million |
+16.36pp |
| 2019-12-31 | 8.42% | ₩22.74 Billion ≈ $15.41 Million |
₩269.93 Billion ≈ $182.92 Million |
-8.70pp |
| 2018-12-31 | 17.12% | ₩44.20 Billion ≈ $29.95 Million |
₩258.19 Billion ≈ $174.97 Million |
-27.64pp |
| 2017-12-31 | 44.75% | ₩84.60 Billion ≈ $57.33 Million |
₩189.03 Billion ≈ $128.11 Million |
-1.79pp |
| 2016-12-31 | 46.55% | ₩83.48 Billion ≈ $56.57 Million |
₩179.33 Billion ≈ $121.53 Million |
-1.85pp |
| 2015-12-31 | 48.40% | ₩81.95 Billion ≈ $55.54 Million |
₩169.31 Billion ≈ $114.74 Million |
-- |
About Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more